FDA Reproductive Health Drugs Cmte. returns
Executive Summary
FDA's Reproductive Health Drugs Adivisory Committee will break a three year hiatus with a Sept. 29 meeting on clinical trial design issues and outcome measures for drugs seeking indications for induction of ovulation and pregnancy in anovulatory infertile women and development of multiple follicles in pregnancy in ovulatory women participating in assisted reproductive technology programs. It is the first meeting of the committee since Sept. 12, 2000, and since its reconstitution with new members in December 2002 (1"The Pink Sheet" Jan. 6, 2003, p. 15)...
You may also be interested in...
FDA Reproductive Health Cmte. Line-Up Set; First Priority Will Be WHI Results
The new roster of FDA's Reproductive Health Drugs Advisory Committee includes two members who have conducted research or educational activities on hormone replacement therapy sponsored by Wyeth
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.